Skip to main content
TipRanks
Go Ultimate75% OFF

Argent Biopharma (H5O0) AI Stock Analysis

1 Followers
DE:H5O0

Argent Biopharma

(Frankfurt:H5O0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving cash burnThe reduction in operating cash outflow shows some improvement in near-term cash discipline, even though Argent Biopharma remains cash-flow negative. If sustained, lower burn could extend funding runway and give management more time to improve products, sales, and profitability.
Negative Factors
Severe revenue contractionA sharp revenue decline following several years of contraction signals weakening commercial scale and reduces the base from which Argent Biopharma can recover. Persistent top-line pressure also makes fixed costs harder to absorb and increases dependence on external funding or a successful product turnaround.

Argent Biopharma (H5O0) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%DE:H5O0-23.53%EWG+3.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.64M
Dividend Yield
―
Average Volume (3M)
3,434
Price to Earnings (P/E)
-0.2
Beta (1Y)
-2.72
Revenue Growth
10.33%
EPS Growth
76.52%
Country
Germany
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Argent Biopharma Business Overview & Revenue Model

Company Description

Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments d...

Argent Biopharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:H5O0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:CANAU:CAN53NeutralAUD 9.96M0.3064.70%―-24.22%―
AU:LGPAU:LGP52NeutralAUD 54.65M-14.13-1.67%―15.21%-141.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:VITAU:VIT44NeutralAUD 11.93M-2.69-9.80%―5.74%-222.22%
AU:EXLAU:EXL43NeutralAUD 2.72M-0.59-50.35%―-4.87%-9.78%
AU:PKPAU:PKP39UnderperformAUD 18.75M-5.074388.00%―-19.73%50.34%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:H5O0AU:EXLAU:CANAU:LGPAU:PKPAU:VITDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:H5O0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:H5O0Argent Biopharma Ltd0.03-0.01-23.53%
AU:EXLElixinol Wellness Ltd0.010.0050.00%
AU:CANCann Group Ltd.0.01-0.00-9.09%
AU:LGPLittle Green Pharma Ltd.0.07-0.07-52.86%
AU:PKPAlthea Group Holdings Ltd.0.01-0.01-30.00%
AU:VITCronos Australia Ltd.0.02-0.05-71.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.